Anti-citrullinated peptide antibodies and the progression of radiographic joint erosions in patients with early rheumatoid arthritis treated with FIN-RACo combination and single disease-modifying antirheumatic drug strategies

Clinical and Experimental Rheumatology

Hannu Kautiainen¹  Anu Mustila¹  Anna-Maija Haapala¹  Pekka Hannonen¹  Jorma Ilonen¹  Leena Laasonen¹  Markku Korpela¹  Timo Möttönen¹  Reijo Luukkainen¹  Salme Järvenpää¹  Marjatta Leirisalo-Repo¹ 

关键词: Antibodies to cyclic citrullinated peptide (ACPAs);    radiographic progression;    FIN-RACo;    DMARDs;    Radiographic progression;    ACPAs;    DMARDs;   

DOI  :  

学科分类：医学（综合）

来源: Pacini Editore SpA

【 摘 要 】

OBJECTIVES: To evaluate the impact of antibodies to cyclic citrullinated peptide (ACPAs) on radiographic progression in patients with early rheumatoid arthritis (RA) initially treated either with a combination of 3 disease-modifying antirheumatic drugs (DMARDs) or with a single DMARD. METHODS: This study included 129 patients with early active RA initially randomised to treatment either with a combination of methotrexate, sulfasalazine, hydroxychloroquine, and prednisolone (FIN-RACo) (n=69) or with a single DMARD (initially sulfalasalazine) with or without prednisolone (SINGLE) (n=60). After 2 years, the use of DMARDs and prednisolone became unrestricted. Radiographic progression in hands and feet was assessed at baseline and at 1, 2, 3, 4 and 5 years. ACPAs at baseline were determined with enzyme immunoassay. RESULTS: ACPAs were positive in 92 (71%) patients. ACPA-positive vs. negative patients were more frequently rheumatoid factor (RF) positive (83% vs. 22%, p

【 授权许可】

Unknown